8/3/2019 2012_01_20_gmp_cp_en

1/6

8/3/2019 2012_01_20_gmp_cp_en

2/6

http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20110721:EN:PDFhttp://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20110721:EN:PDFhttp://ec.europa.eu/transparency/regrinmailto:sanco-pharmaceuticals-d6@ec.europa.eumailto:sanco-pharmaceuticals-d6@ec.europa.eu

8/3/2019 2012_01_20_gmp_cp_en

3/6

http://ec.europa.eu/health/files/eudralex/vol-4/2007_09_gmp_part2_en.pdfhttp://ec.europa.eu/health/files/eudralex/vol-4/2007_09_gmp_part2_en.pdfhttp://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htmhttp://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32003L0094:EN:NOThttp://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32003L0094:EN:NOT

8/3/2019 2012_01_20_gmp_cp_en

4/6

8/3/2019 2012_01_20_gmp_cp_en

5/6

8/3/2019 2012_01_20_gmp_cp_en

6/6